STOCK TITAN

[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Colony Bankcorp Inc. (CBAN) Form 4 highlights: Director Matthew D. Reed reported the grant of 969 restricted shares on 07/15/2025. Following the award, he now directly owns 16,736 common shares, up roughly 6% from the pre-grant level (~15,767). In addition, Reed holds 448 shares indirectly through an IRA for Kennedy K. Reed. No derivative securities, sales, or open-market purchases were disclosed.

The filing reflects a routine equity-based compensation grant and modestly increases insider ownership, which can align director incentives with shareholder interests. However, because the shares were granted (not purchased with personal funds), the transaction’s immediate signaling value is limited. No other material events, financial metrics, or changes to ownership structure were reported.

Colony Bankcorp Inc. (CBAN) Modulo 4 evidenzia: Il direttore Matthew D. Reed ha riportato la concessione di 969 azioni vincolate il 15/07/2025. A seguito di questa assegnazione, ora possiede direttamente 16.736 azioni ordinarie, con un aumento di circa il 6% rispetto al livello precedente alla concessione (~15.767). Inoltre, Reed detiene 448 azioni indirettamente tramite un IRA per Kennedy K. Reed. Non sono stati divulgati titoli derivati, vendite o acquisti sul mercato aperto.

La comunicazione riflette una normale assegnazione di compensi basata su azioni e aumenta modestamente la proprietà interna, allineando potenzialmente gli incentivi del direttore con gli interessi degli azionisti. Tuttavia, poiché le azioni sono state assegnate (e non acquistate con fondi personali), il valore segnaletico immediato della transazione è limitato. Non sono stati riportati altri eventi rilevanti, metriche finanziarie o modifiche alla struttura proprietaria.

Colony Bankcorp Inc. (CBAN) Formulario 4 destaca: El director Matthew D. Reed reportó la concesión de 969 acciones restringidas el 15/07/2025. Tras esta adjudicación, ahora posee directamente 16,736 acciones comunes, un aumento aproximado del 6% respecto al nivel previo a la concesión (~15,767). Además, Reed posee 448 acciones de manera indirecta a través de una IRA para Kennedy K. Reed. No se divulgaron valores derivados, ventas ni compras en el mercado abierto.

La presentación refleja una concesión rutinaria de compensación basada en acciones y aumenta modestamente la propiedad interna, lo que puede alinear los incentivos del director con los intereses de los accionistas. Sin embargo, dado que las acciones fueron concedidas (y no compradas con fondos personales), el valor señal inmediato de la transacción es limitado. No se reportaron otros eventos materiales, métricas financieras ni cambios en la estructura de propiedad.

Colony Bankcorp Inc. (CBAN) Form 4 주요 내용: 이사 Matthew D. Reed가 2025년 7월 15일에 969주의 제한 주식 부여를 보고했습니다. 이번 부여 이후 그는 현재 직접 16,736주의 보통주를 보유하고 있으며, 부여 전 약 15,767주 대비 약 6% 증가했습니다. 또한 Reed는 Kennedy K. Reed를 위한 IRA를 통해 간접적으로 448주를 보유하고 있습니다. 파생상품, 매도, 또는 공개 시장 매수 내역은 공개되지 않았습니다.

이번 신고는 일반적인 주식 기반 보상 부여를 반영하며 내부자 지분을 소폭 증가시켜 이사의 인센티브를 주주 이익과 일치시킬 수 있습니다. 다만 주식이 부여된 것이지 개인 자금으로 매수한 것이 아니므로 거래의 즉각적인 신호 가치는 제한적입니다. 기타 중요한 사건, 재무 지표 또는 소유 구조 변경은 보고되지 않았습니다.

Colony Bankcorp Inc. (CBAN) Points clés du Formulaire 4 : Le directeur Matthew D. Reed a déclaré l'octroi de 969 actions restreintes le 15/07/2025. Suite à cette attribution, il détient désormais directement 16 736 actions ordinaires, soit une augmentation d'environ 6 % par rapport au niveau avant l'attribution (~15 767). De plus, Reed détient 448 actions indirectement via un IRA pour Kennedy K. Reed. Aucun titre dérivé, vente ou achat sur le marché ouvert n'a été divulgué.

Cette déclaration reflète une attribution de rémunération en actions de routine et augmente modestement la détention d'initiés, ce qui peut aligner les incitations du directeur avec les intérêts des actionnaires. Toutefois, comme les actions ont été attribuées (et non achetées avec des fonds personnels), la valeur indicative immédiate de la transaction est limitée. Aucun autre événement important, indicateur financier ou changement dans la structure de propriété n'a été signalé.

Colony Bankcorp Inc. (CBAN) Form 4 Highlights: Direktor Matthew D. Reed meldete die Zuteilung von 969 eingeschränkten Aktien am 15.07.2025. Nach der Zuteilung besitzt er nun direkt 16.736 Stammaktien, was einem Anstieg von etwa 6 % gegenüber dem Stand vor der Zuteilung (~15.767) entspricht. Zusätzlich hält Reed 448 Aktien indirekt über ein IRA für Kennedy K. Reed. Keine Derivate, Verkäufe oder Käufe am offenen Markt wurden offengelegt.

Die Meldung spiegelt eine routinemäßige aktienbasierte Vergütung wider und erhöht den Insiderbesitz leicht, was die Anreize des Direktors mit den Interessen der Aktionäre in Einklang bringen kann. Da die Aktien jedoch gewährt wurden (nicht mit eigenen Mitteln gekauft), ist der unmittelbare Signaleffekt der Transaktion begrenzt. Es wurden keine weiteren wesentlichen Ereignisse, Finanzkennzahlen oder Änderungen in der Besitzstruktur gemeldet.

Positive
  • Director ownership rises ~6%, marginally improving management-shareholder alignment
Negative
  • None.

Insights

TL;DR: Routine restricted-stock grant lifts director’s stake 6%; alignment positive but signal limited versus open-market buy.

Restricted stock awards are standard board compensation. Reed’s direct ownership rises to 16,736 shares, keeping directors’ interests aligned with investors. Because no cash outlay was made, market shouldn’t infer the same confidence as an outright purchase. No red flags—no sales, pledges, or derivative positions—so governance risk remains low. Impact: neutral-positive.

TL;DR: Small, non-cash insider acquisition; negligible valuation impact.

The 969-share grant equates to <1% of CBAN’s ~9.0 m shares outstanding, therefore immaterial to float or supply/demand. Because the stock was awarded, not bought, it doesn’t convey incremental bullish sentiment. I view the event as routine and non-impactful for portfolio positioning.

Colony Bankcorp Inc. (CBAN) Modulo 4 evidenzia: Il direttore Matthew D. Reed ha riportato la concessione di 969 azioni vincolate il 15/07/2025. A seguito di questa assegnazione, ora possiede direttamente 16.736 azioni ordinarie, con un aumento di circa il 6% rispetto al livello precedente alla concessione (~15.767). Inoltre, Reed detiene 448 azioni indirettamente tramite un IRA per Kennedy K. Reed. Non sono stati divulgati titoli derivati, vendite o acquisti sul mercato aperto.

La comunicazione riflette una normale assegnazione di compensi basata su azioni e aumenta modestamente la proprietà interna, allineando potenzialmente gli incentivi del direttore con gli interessi degli azionisti. Tuttavia, poiché le azioni sono state assegnate (e non acquistate con fondi personali), il valore segnaletico immediato della transazione è limitato. Non sono stati riportati altri eventi rilevanti, metriche finanziarie o modifiche alla struttura proprietaria.

Colony Bankcorp Inc. (CBAN) Formulario 4 destaca: El director Matthew D. Reed reportó la concesión de 969 acciones restringidas el 15/07/2025. Tras esta adjudicación, ahora posee directamente 16,736 acciones comunes, un aumento aproximado del 6% respecto al nivel previo a la concesión (~15,767). Además, Reed posee 448 acciones de manera indirecta a través de una IRA para Kennedy K. Reed. No se divulgaron valores derivados, ventas ni compras en el mercado abierto.

La presentación refleja una concesión rutinaria de compensación basada en acciones y aumenta modestamente la propiedad interna, lo que puede alinear los incentivos del director con los intereses de los accionistas. Sin embargo, dado que las acciones fueron concedidas (y no compradas con fondos personales), el valor señal inmediato de la transacción es limitado. No se reportaron otros eventos materiales, métricas financieras ni cambios en la estructura de propiedad.

Colony Bankcorp Inc. (CBAN) Form 4 주요 내용: 이사 Matthew D. Reed가 2025년 7월 15일에 969주의 제한 주식 부여를 보고했습니다. 이번 부여 이후 그는 현재 직접 16,736주의 보통주를 보유하고 있으며, 부여 전 약 15,767주 대비 약 6% 증가했습니다. 또한 Reed는 Kennedy K. Reed를 위한 IRA를 통해 간접적으로 448주를 보유하고 있습니다. 파생상품, 매도, 또는 공개 시장 매수 내역은 공개되지 않았습니다.

이번 신고는 일반적인 주식 기반 보상 부여를 반영하며 내부자 지분을 소폭 증가시켜 이사의 인센티브를 주주 이익과 일치시킬 수 있습니다. 다만 주식이 부여된 것이지 개인 자금으로 매수한 것이 아니므로 거래의 즉각적인 신호 가치는 제한적입니다. 기타 중요한 사건, 재무 지표 또는 소유 구조 변경은 보고되지 않았습니다.

Colony Bankcorp Inc. (CBAN) Points clés du Formulaire 4 : Le directeur Matthew D. Reed a déclaré l'octroi de 969 actions restreintes le 15/07/2025. Suite à cette attribution, il détient désormais directement 16 736 actions ordinaires, soit une augmentation d'environ 6 % par rapport au niveau avant l'attribution (~15 767). De plus, Reed détient 448 actions indirectement via un IRA pour Kennedy K. Reed. Aucun titre dérivé, vente ou achat sur le marché ouvert n'a été divulgué.

Cette déclaration reflète une attribution de rémunération en actions de routine et augmente modestement la détention d'initiés, ce qui peut aligner les incitations du directeur avec les intérêts des actionnaires. Toutefois, comme les actions ont été attribuées (et non achetées avec des fonds personnels), la valeur indicative immédiate de la transaction est limitée. Aucun autre événement important, indicateur financier ou changement dans la structure de propriété n'a été signalé.

Colony Bankcorp Inc. (CBAN) Form 4 Highlights: Direktor Matthew D. Reed meldete die Zuteilung von 969 eingeschränkten Aktien am 15.07.2025. Nach der Zuteilung besitzt er nun direkt 16.736 Stammaktien, was einem Anstieg von etwa 6 % gegenüber dem Stand vor der Zuteilung (~15.767) entspricht. Zusätzlich hält Reed 448 Aktien indirekt über ein IRA für Kennedy K. Reed. Keine Derivate, Verkäufe oder Käufe am offenen Markt wurden offengelegt.

Die Meldung spiegelt eine routinemäßige aktienbasierte Vergütung wider und erhöht den Insiderbesitz leicht, was die Anreize des Direktors mit den Interessen der Aktionäre in Einklang bringen kann. Da die Aktien jedoch gewährt wurden (nicht mit eigenen Mitteln gekauft), ist der unmittelbare Signaleffekt der Transaktion begrenzt. Es wurden keine weiteren wesentlichen Ereignisse, Finanzkennzahlen oder Änderungen in der Besitzstruktur gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Breedlove Robert Charles

(Last) (First) (Middle)
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102

(Street)
FLORHAM PARK NJ 07932

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Principal Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/16/2025 S(1) 1,692 D $8.3639(2) 48,392 D
Common Stock 5,108.4 I By 401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
2. The price reported in Column 4 is a weighted average price. These shares were sold in mutliple transactions at prices $8.364 and $8.35. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Steven Basta, Attorney-in-Fact for Robert Charles Breedlove 07/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CBAN shares did Director Matthew D. Reed acquire?

He received 969 restricted shares on 07/15/2025.

What is Reed’s total direct ownership after the transaction?

He now directly holds 16,736 CBAN common shares.

Were any CBAN shares sold in this Form 4?

No. The filing only reports an acquisition; there were no dispositions.

Does the filing include derivative securities or options?

No derivative securities were reported; the table for derivatives is blank.

Is the acquisition an open-market purchase?

No, it is a restricted stock award grant, part of board compensation.
Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

PHAT Rankings

PHAT Latest News

PHAT Latest SEC Filings

PHAT Stock Data

632.52M
54.40M
3.77%
97.01%
20.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
FLORHAM PARK